Industry Briefs: Jan. 30, 2012
A roundup of other company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Aptar Pharma has opened a new manufacturing site near Mumbai, India.
FDA has approved Pfizer’s Inlyta (axitinib), a kinase inhibitor for treating advanced renal cell carcinoma.
FDA has approved Roche’s Erivedge (vismodegib) capsule for treating advanced basal cell carcinoma.
Lpath has temporarily suspended dosing of iSONEP, for treating age-related macular degeneration, in clinical trials due to cGMP compliance issues at the contract fill–finish source.
Roche has formally issued an offer to acquire all outstanding shares of Illumina for $44.50 per share in cash, or an aggregate of approximately $5.7 billion.
Royal DSM and Indoco Remedies have formed a commercialization agreement for eight APIs.
Valeant Pharmaceuticals has withdrawn its offer to acquire ISTA Pharmaceuticals for $7.50 per share in cash.
Watson Pharmaceuticals announced plans to establish a New Jersey-based R&D technology center to support generic-drug pharmaceutical product development.
People News
GlaxoSmithKline has announced changes to its board of directors.
Octagon Research Solutions has appointed Gina L. Schmidt to manage the company’s global regulatory services division.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
